Although tyrosine kinase inhibitors (TKIs) that target mutant EGFR in NSCLC have been successful in controlling tumor growth, they may also invariably induce acquired resistance due to EGFR mutations [[47], [48], [49]]. This evidence concerns the gene EGFR and neoplasm.